WORLD
Daewoong tests camostat mesilate for treatment of COVID-19
WORLD

Daewoong tests camostat mesilate for treatment of COVID-19

Published: July 7, 2020  |  1 min read, 229 words
WRITTEN BY
Your review will affect the following:
> >[Yonhap Photo]SEOUL -- Camostat mesilate, a potent serine protease inhibitor sold by Daewoong Pharmaceutical under the brand of Foistar, has been approved by the Ministry of Food and Drug Safety, a government public health agency, to go ahead with second-stage clinical trials to prove its efficacy in treating COVID-19.In clinical trials, 90 patients with mild or secondary symptoms will be given drugs for up to 14 days to determine the effectiveness of Foistar tablets, which are used to treat to treat chronic pancreatitis and postoperative reflux esophagitis. Daewoong plans to carry out... READ MORE
CRITIC
N/A
N/Ano rating
Critic Reviews: N/A
We calculate ratings after a minimum of three reviews.
USER
N/A
N/Ano rating
User Reviews: N/A
We calculate ratings after a minimum of three reviews.
TOP REVIEWS
There are no reviews yet.

CRITIC REVIEWS

There don't seem to be any reviews yet.

PUBLIC REVIEWS

There don't seem to be any reviews yet.